The USPTO Issues a Patent to Cellular Engineering Technologies for Producing a Safer Induced Pluripotent Stem Cell.
March 8, 2022
August 17, 2021
Cellular Engineering Technologies has Been Awarded a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Institutes of Health to Improve Reproducible and Safer Pluripotent Stem Cells.
August 14, 2020
Cellular Engineering Technologies, the John Paul II Medical Research Institute and the University of Iowa Create the First Virus-Free and Oncogene-Free Induced Pluripotent Stem Cell (iPSC) Technology to Produce Safer Pluripotent Stem Cells from Cord Blood and Peripheral Blood.
November 30, 2018
November 3, 2017
Cellular Engineering Technologies and the John Paul II Medical Research Institute Report New Approach to Create Myc and Lin28-Free Induced Pluripotent Stem Cells.
May 12, 2017
KGAN-TV CBS2 News Iowa, June 2014
Iowa Organizations Join Forces to Offer Cutting-Edge Personalized Cancer Diagnosis and Treatment to Patients.
CET now provides customize induced pluripotent stem (iPS) cell reprograming service and products.
Cellular Engineering Technologies, Inc. (CET) now offers patients-specific Human Bronchial Epithelial cells.
Cellular Engineering Technologies, Inc. (CET) now offers Human
Foreskin Fibroblast (HFF) and Keratinocyte cells.
Cellular Engineering Technology Receives DEMO Fund Grant from the Iowa Department of Economic Development (IDED) to Develop Novel Induced Pluripotent Stem Cells.
Cellular Engineering Technologies Inc Receives 2009 Best of Business Award From Small Business Commerce Association.